BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19

Heterologous prime/boost vaccination with a vector-based approach (ChAdOx-1nCov-19, ChAd) followed by an mRNA vaccine (e.g. BNT162b2, BNT) has been reported to be superior in inducing protective immunity compared to repeated application of the same vaccine. However, data comparing immunity decline a...

Descripción completa

Detalles Bibliográficos
Autores principales: Behrens, Georg M. N., Barros-Martins, Joana, Cossmann, Anne, Ramos, Gema Morillas, Stankov, Metodi V., Odak, Ivan, Dopfer-Jablonka, Alexandra, Hetzel, Laura, Köhler, Miriam, Patzer, Gwendolyn, Binz, Christoph, Ritter, Christiane, Friedrichsen, Michaela, Schultze-Florey, Christian, Ravens, Inga, Willenzon, Stefanie, Bubke, Anja, Ristenpart, Jasmin, Janssen, Anika, Ssebyatika, George, Krähling, Verena, Bernhardt, Günter, Hoffmann, Markus, Pöhlmann, Stefan, Krey, Thomas, Bošnjak, Berislav, Hammerschmidt, Swantje I., Förster, Reinhold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387891/
https://www.ncbi.nlm.nih.gov/pubmed/35982040
http://dx.doi.org/10.1038/s41467-022-32527-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387891/
https://www.ncbi.nlm.nih.gov/pubmed/35982040
http://dx.doi.org/10.1038/s41467-022-32527-2

Ejemplares similares